Clinical Trial Update: TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating tamoxifen in combination with ribociclib (LEE011) for advanced ER+ (HER2-negative) breast cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Ribociclib (LEE011) (ribociclib)
• Tamoxifen (tamoxifen)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Breast Cancer, Breast Cancer - Female | Phase 1 | Status: COMPLETED | Results posted: 2019-06-03